KRAS and non-small cell lung carcinoma: Our results revealed that SHP2 and XIAP are potential synthetic lethal partners, and embelin provides the backbone for the development of novel SHP2/XIAP dual‐targeting inhibitors to yield innovative therapeutic strategies for the alleviation of KRAS‐mutant NSCLC.